Trinity Investors Celebrates Nuclein’s Dual FDA Clearance and CLIA Waiver for DASH® SARS-CoV-2 & Flu A/B Test

New DASH® Rapid PCR System Delivers Lab-Quality Results in 15 MinutesSOUTHLAKE, Texas, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Trinity Investors, a leading alternative asset management firm, proudly announces a significant milestone achieved by portfolio company Nuclein, LLC, a pioneer in rapid, point-of-care molecular diagnostics. Nuclein has secured U.S. Food and Drug Administration (FDA) 510(k) clearance and a Clinical Laboratory Improvement Amendments (CLIA) waiver for its DASH® SARS-CoV-2 & Flu A/B Test, des ...